Johnson & Johnson EBITDA 2010-2024 | JNJ

Johnson & Johnson annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Johnson & Johnson EBITDA for the quarter ending March 31, 2024 was $5.965B, a 27.24% increase year-over-year.
  • Johnson & Johnson EBITDA for the twelve months ending March 31, 2024 was $24.581B, a 9.28% decline year-over-year.
  • Johnson & Johnson 2023 annual EBITDA was $24.581B, a 9.28% decline from 2022.
  • Johnson & Johnson 2022 annual EBITDA was $27.095B, a 1.09% increase from 2021.
  • Johnson & Johnson 2021 annual EBITDA was $26.804B, a 11.5% increase from 2020.
Johnson & Johnson Annual EBITDA
(Millions of US $)
2023 $24,581
2022 $27,095
2021 $26,804
2020 $24,040
2019 $25,012
2018 $26,544
2017 $24,634
2016 $24,651
2015 $23,622
2014 $25,058
2013 $20,131
2012 $18,037
2011 $16,181
2010 $20,448
2009 $19,070
Johnson & Johnson Quarterly EBITDA
(Millions of US $)
2023-12-31 $5,965
2023-09-30 $7,612
2023-06-30 $9,411
2023-03-31 $1,593
2022-12-31 $4,688
2022-09-30 $7,058
2022-06-30 $7,686
2022-03-31 $7,663
2021-12-31 $3,154
2021-09-30 $5,696
2021-06-30 $8,553
2021-03-31 $9,401
2020-12-31 $3,687
2020-09-30 $6,275
2020-06-30 $5,730
2020-03-31 $8,348
2019-12-31 $6,200
2019-09-30 $3,511
2019-06-30 $8,917
2019-03-31 $6,384
2018-12-31 $5,303
2018-09-30 $6,572
2018-06-30 $7,069
2018-03-31 $7,600
2017-12-31 $4,788
2017-09-30 $6,804
2017-06-30 $6,230
2017-03-31 $6,812
2016-12-31 $5,663
2016-09-30 $6,478
2016-06-30 $6,082
2016-03-31 $6,428
2015-12-31 $5,004
2015-09-30 $5,206
2015-06-30 $6,785
2015-03-31 $6,627
2014-12-31 $3,850
2014-09-30 $7,897
2014-06-30 $6,720
2014-03-31 $6,591
2013-12-31 $4,004
2013-09-30 $4,766
2013-06-30 $5,918
2013-03-31 $5,443
2012-12-31 $4,261
2012-09-30 $4,750
2012-06-30 $3,044
2012-03-31 $5,982
2011-12-31 $1,379
2011-09-30 $5,045
2011-06-30 $4,346
2011-03-31 $5,411
2010-12-31 $3,159
2010-09-30 $5,065
2010-06-30 $5,075
2010-03-31 $7,149
2009-12-31 $3,453
2009-09-30 $5,090
2009-06-30 $5,077
2009-03-31 $5,450
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $356.431B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67